Department of Gynecologic Oncology & Department of Clinical Trial & Research, Netaji Subhas Chandra Bose Cancer Hospital, 3081, Nayabad Avenue, 8D, Mathur Sen Garden Lane, Kolkata, 700094, India.
Med Oncol. 2022 Apr 28;39(5):67. doi: 10.1007/s12032-022-01672-5.
In recent years, approval of some immunotherapy based on markers such as dMMR, tumour mutational burden and other few such markers is not received well as shown in post-approval data published. The context of such approvals and controversies is discussed briefly.
近年来，一些基于标志物的免疫疗法（如 dMMR、肿瘤突变负荷和其他少数标志物）的批准情况并不理想，正如已公布的批准后数据所显示的那样。简要讨论了这些批准和争议的背景。
